120 related articles for article (PubMed ID: 37220017)
1. Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In Advanced Melanoma Using Mutations and Copy Number Variations.
Zhang L; Cao L; Li S; Wang L; Song Y; Huang Y; Xu Z; He J; Wang M; Li K
J Immunother; 2023 Jul-Aug 01; 46(6):221-231. PubMed ID: 37220017
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.
Pérottet J; Le Goff E; Legoupil D; Quéré G; Schick U; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):161-165. PubMed ID: 32044885
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
4. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
[TBL] [Abstract][Full Text] [Related]
5. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
6. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
7. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
8. Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
Smithy JW; Moore LM; Pelekanou V; Rehman J; Gaule P; Wong PF; Neumeister VM; Sznol M; Kluger HM; Rimm DL
J Immunother Cancer; 2017; 5():25. PubMed ID: 28331615
[TBL] [Abstract][Full Text] [Related]
9. Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
Dupuis F; Lamant L; Gerard E; Torossian N; Chaltiel L; Filleron T; Beylot-Barry M; Dutriaux C; Prey S; Gros A; Jullie ML; Meyer N; Vergier B
Br J Cancer; 2018 Jul; 119(2):193-199. PubMed ID: 29973670
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
Front Immunol; 2022; 13():871756. PubMed ID: 35990677
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.
Mu W; Jiang L; Shi Y; Tunali I; Gray JE; Katsoulakis E; Tian J; Gillies RJ; Schabath MB
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135101
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
14. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.
Yang Y; Yang J; Shen L; Chen J; Xia L; Ni B; Ge L; Wang Y; Lu S
Am J Transl Res; 2021; 13(2):743-756. PubMed ID: 33594323
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
[TBL] [Abstract][Full Text] [Related]
16. High response rate to PD-1 blockade in desmoplastic melanomas.
Eroglu Z; Zaretsky JM; Hu-Lieskovan S; Kim DW; Algazi A; Johnson DB; Liniker E; Ben Kong ; Munhoz R; Rapisuwon S; Gherardini PF; Chmielowski B; Wang X; Shintaku IP; Wei C; Sosman JA; Joseph RW; Postow MA; Carlino MS; Hwu WJ; Scolyer RA; Messina J; Cochran AJ; Long GV; Ribas A
Nature; 2018 Jan; 553(7688):347-350. PubMed ID: 29320474
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
20. Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.
Liu C; He H; Li X; Su MA; Cao Y
Br J Cancer; 2019 Feb; 120(3):346-355. PubMed ID: 30587849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
